FOLLOW US

In a high-stakes move that could reshape the cancer treatment landscape, Gilead to acquire Arcellx became the headline Monday as Gilead Sciences Inc. unveiled a $7.8 billion agreement to buy clinical-stage biotech firm Arcellx Inc..

The deal values Arcellx at $115 per share in cash plus a contingent value right worth $5 per share, underscoring Gilead’s aggressive push to deepen its oncology pipeline. Like a pharmaceutical chess move several plays ahead, the transaction signals Gilead’s confidence in a therapy it believes could become a cornerstone in blood cancer treatment.

Tender Offer and Premium Surge

Under the agreement, a Gilead subsidiary will launch a tender offer for all outstanding Arcellx shares not already in its hands. Gilead already owns about 11.5% of Arcellx stock, giving it a meaningful foothold before this full takeover bid.

The $115-per-share cash offer represents a 68% premium to Arcellx’s 30-day average share price as of Friday. Investors reacted swiftly. Arcellx shares soared more than 77% on Monday, reflecting Wall Street’s appetite for the blockbuster pairing.

Legal counsel for the transaction includes Ropes & Gray LLP advising Gilead, while Wilson Sonsini Goodrich & Rosati PC is representing Arcellx.

Building on an Existing Alliance

Anito-cel at the Center of the Deal

The acquisition builds on a collaboration between Gilead’s Kite unit and Arcellx to co-develop and commercialize Arcellx’s lead therapy, anitocabtagene autoleucel — known as anito-cel — a cell therapy targeting multiple myeloma, a type of blood cancer.

Anito-cel is being developed as a fourth-line treatment for patients with relapsed or refractory multiple myeloma. But Gilead sees further horizons.

“Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy,” Daniel O’Day, Gilead’s chair and CEO, said in a statement. He added that the platform technology behind the therapy could also bolster Gilead’s broader ambitions in in-vivo cell therapy, reinforcing its oncology and inflammation portfolio.

The regulatory clock is already ticking. The U.S. Food and Drug Administration has accepted a biologics license application for anito-cel, setting a Prescription Drug User Fee Act action date of Dec. 23.

Leadership Weighs In

Rami Elghandour, chair and CEO of Arcellx, described Gilead as a “world-class partner,” praising the therapy’s promise for patients and clinicians. He also credited Arcellx’s employees and clinical trial participants for bringing the treatment this far.

The boards of both companies have approved the deal, which is expected to close in the second quarter of 2026, subject to customary conditions. Those include regulatory approvals and the tender of a majority of Arcellx’s outstanding shares.

Advisers and Deal Architects

Financial heavyweights are steering the transaction. BofA Securities Inc. and Morgan Stanley & Co. LLC are advising Gilead.

On Arcellx’s side, Centerview Partners LLC is serving as exclusive financial adviser, with legal guidance to Centerview provided by a team at Kirkland & Ellis LLP led by partners Laura Knoll and Graham Robinson.

The Ropes & Gray team advising Gilead is led by partner Emily Oldshue. The Wilson Sonsini team representing Arcellx is led by partners Rob Ishii, Dan Koeppen and Ross Tanaka.

As the biotech sector navigates volatile markets and regulatory headwinds, this acquisition lands like a thunderclap — a calculated gamble that the next breakthrough in cancer therapy will not just treat disease, but redefine the battlefield.